Frontotemporal Dementia Market Insights, Epidemiology, Treatment Landscape, Emerging Drugs and Leading Companies

DelveInsight’s Frontotemporal Dementia Market Insights report delivers an in-depth understanding of the Hypovolemic Shock, historical and forecasted epidemiology as well as the Hypovolemic Shock market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Key Highlights from the Frontotemporal Dementia Market Report

• As per the study conducted by E. Ratnavalli et al. 2002, the prevalence of early-onset Frontotemporal Dementia and Alzheimer’s disease were the same which was estimated to be 15 per 100,000 in the 45- to 64-year-old population. The mean age at onset of Frontotemporal Dementia was 52.8 years and there was a striking male preponderance.
• According to Chiadikaobi U Onyike et al. Point prevalence was projected to be 15–22 per 100,000, with a prevalence of 2.7–4.1 per 100,000. Around a quarter of the cases begin later in life.
• According to a study conducted by Juan Joseph Young et al. in 2017, the prevalence of FTD in people aged 45 to 65 years ranged from 15 to 22 per 100,000 people in the United States, with incidence rates ranging from 2.7 to 4.1 per 100,000 in the same age group.
• Key Pipeline Therapies in the Frontotemporal Dementia market include LMTX (TauRx Therapeutics) and AL001 (Alector).
• Major companies involved in the Frontotemporal Dementia market are TauRx Therapeutics, Alector, among others.
• The increase in FTD Market Size is a direct consequence of the increasing prevalent population of Frontotemporal Dementia patients in the 7MM.

Visit to learn more @ Frontotemporal Dementia Market Analysis and Forecast

The Frontotemporal Dementia market report provides current treatment practices, emerging drugs, Frontotemporal Dementia market share of the individual therapies, current and forecasted Frontotemporal Dementia market size during the study period of 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).

Frontotemporal Dementia: Disease Overview

Frontotemporal Dementia (FTD) is a broad term that refers to a variety of rare brain disorders that mainly affect the frontal and temporal lobes. Parts of these lobes shrink in this disorder (atrophy). The presence of proteins TDP43 and tau, which specifically causes damage to the temporal and frontal lobes of the brain, is the primary cause of frontotemporal lobe degeneration.

Frontotemporal Dementia Epidemiology Segmentation

The Frontotemporal Dementia report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

• Frontotemporal Dementia Prevalence
• Frontotemporal Dementia Gender-Specific Prevalent Cases
• Frontotemporal Dementia Age-Specific Prevalent Cases
• Frontotemporal Dementia Diagnosed and Treatable Cases

To know more about epidemiology visit, Frontotemporal Dementia Epidemiology

Frontotemporal Dementia Treatment Landscape

There is currently no targeted therapy for the cure of Frontotemporal Dementia (FTD), although certain symptomatic therapies are provided to patients with Frontotemporal Dementia.

The major treatment options in the FTD therapy market are:

• Antidepressants Drugs (fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, bupropion, and mirtazapine)
• Antipsychotic Medications (olanzapine or quetiapine)
• Speech and Language Therapy
• Occupational Therapy

Frontotemporal Dementia Market

Leading pharmaceutical companies including TauRx Therapeutics, Alector, and others are expected to enter the Frontotemporal Dementia market with new therapies.

The introduction of LMTX (TauRx Therapeutics) and AL001 (Alector) is expected to give the Frontotemporal Dementia market a significant boost in the forecast period 2017-30 in the 7MM.

Furthermore, extensive R&D in the domain, as well as increasing Frontotemporal Dementia prevalence, are driving the Frontotemporal Dementia market forward.

Frontotemporal Dementia Emerging Therapies and Leading Companies

• LMTX: TauRx Therapeutics
• AL001: Alector

Know more about emerging therapies and companies @ Frontotemporal Dementia Emerging Therapies and Leading Companies

Table of Content:

1.	Report Introduction
2.	Frontotemporal Dementia: Market Overview at a Glance
3.	Disease Background and Overview: Frontotemporal Dementia
4.	Epidemiology and Patient Population
5.	Frontotemporal Dementia: Country-Wise Epidemiology
6.	United States Epidemiology
7.	EU–5 Countries Epidemiology
8.	Japan Epidemiology
9.	Frontotemporal Dementia: Treatments and Medical Practices
10.	Emerging Therapies
11.	Key Cross Competition
12.	Frontotemporal Dementia Market Size
13.	7MM Frontotemporal Dementia: Country-Wise Market Analysis
14.	United States Market Size
15.	EU5 Market Size
16.	Japan Market Size
17.	Report Methodology
18.	DelveInsight Capabilities
19.	Disclaimer
20.	About DelveInsight

Know more what’s covered in the Frontotemporal Dementia Market Assessment Report  

Related Reports

Familial Chylomicronemia Syndrome Market

Get comprehensive historical and forecast analysis of Familial Chylomicronemia Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novelion Therapeutics, among others.

Intrahepatic Cholangiocarcinoma Market

Get comprehensive historical and forecast analysis of Intrahepatic Cholangiocarcinoma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Incyte Corporation,  Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Qed Therapeutics, among others.

Lamellar Ichthyosis Market

Get comprehensive historical and forecast analysis of Lamellar Ichthyosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Timber Pharmaceuticals, Krystal Biotech, Galderma among others.

Dementia with Diabetes Market

Get comprehensive historical and forecast analysis of Dementia with Diabetes Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novo Nordisk, vTv Therapeutics, among others.

Lewy Body Dementia Market

DelveInsight’s “Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Dementia Market

DelveInsight’s “Vascular Dementia Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Vascular Dementia, historical and forecasted epidemiology as well as the Vascular Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market

DelveInsight’s “Chronic Inflammatory Demyelinating Polyradiculoneuropathy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyradiculoneuropathy , historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyradiculoneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Atopic Dermatitis Market

DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fragile X Syndrome Market

Get comprehensive historical and forecast analysis of Fragile X Syndrome Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Neuren Pharmaceuticals, Ovid Therapeutics, Tetra Therapeutics,  Confluence Pharmaceuticals, Zynerba Pharmaceuticals, among others.

Friedreich’s Ataxia Market

DelveInsight’s “Friedreich’s Ataxia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Friedreich’s Ataxia, historical and forecasted epidemiology as well as the Friedreich’s Ataxia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get in touch with our Business Executive @ Rare disease market insights to know more. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us 

Sandeep Joshi 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Related Post
Metastatic Triple Negative Breast Cancer (mTNBC) Market 2030: Epidemiology Analysis, Key Companies, Emerging Drugs and Competitive Analysis by DelveInsight
Key players such as Phathom Pharmaceuticals and others are developing therapies to enhance treatment modalities in the Zollinger-Ellison Syndrome market
Glioblastoma Multiforme (GBM) Epidemiology: A comprehensive analysis of the Patient Population, Medical Practices, and Forecasted Epidemiology Till 2030
Glioblastoma Pipeline Analysis: 60+ Key Pipeline Therapies and 60+ Key Pharma Players are Looking Out in the Glioblastoma Pipeline Landscape
Triple-Negative Breast Cancer Pipeline: Industry Analysis, Drugs, Pipeline Therapies and Key Companies by DelveInsight

Contact Information:

Sandeep Joshi 
info@delveinsight.com 
+1(919)321-6187